
In this special edition of the View, Dr. Eagle looks at seven studies presented at the recent American Heart Association Conference that could have immediate effects on your practice. First, he discusses ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation…






































